FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First …
WEBFeb 17, 2023 · SYFOVRE™ (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system. SYFOVRE is approved in the United States for the treatment of GA secondary to age-related macular degeneration.
Release Details - Apellis Pharmaceuticals, Inc.
WEBNov 4, 2023 · SYFOVRE ® (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system. SYFOVRE is approved in the United States for the treatment of GA secondary to age-related macular degeneration.
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE …
WEBJul 29, 2023 · SYFOVRE ® (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system. SYFOVRE is approved in the United States for the treatment of GA secondary to age-related macular degeneration.
Europe's CHMP turns down Apellis' pegcetacoplan appeal, …
WEB1 day ago · In the U.S., Syfovre’s GA rollout has been tumultuous thanks to side effects concerns, Medicare hiccups and more. All told, Syfovre generated $154.6 million in 2024’s second quarter. As of ...
Apellis eye drug again turned back in Europe | BioPharma Dive
WEB1 day ago · Apellis cut 25% of its workforce in 2023 in part to focus more resources around Syfovre’s launch. Suvannavejh had previously estimated Syfovre could generate about $367 million in peak yearly sales in Europe. A review of Izervay, meanwhile, is ongoing. Apellis shares fell as much as 10%, to just under $33 apiece, in early trading Friday.
New drug for dry AMD - Syfovre: your questions answered
WEBApr 4, 2023 · In February we shared the exciting news that the Syfovre, the first-ever drug to treat dry age-related macular degeneration (AMD) has been approved in the US. With the support of Apellis Pharmaceuticals, which has brought the drug to market, we answer some of your most frequently asked questions.
Apellis wins FDA approval of first drug for type of vision loss
WEBFeb 17, 2023 · Apellis wins FDA approval of first drug for type of vision loss. The company’s treatment, Syfovre, is cleared for geographic atrophy, a common and irreversible eye condition. But questions linger about its benefit and safety. Published Feb. 17, 2023. Ben Fidler Senior Editor.
FDA Approves First Geographic Atrophy Treatment SYFOVRE
WEBFeb 18, 2023 · In clinical trials, Syfovre™ was shown to reduce the rate of geographic atrophy lesion growth by up to 36% with monthly injection. Dosing is set at about every 25 to 60 days, according to Apellis, the drug’s manufacturer, depending on …
Experts report eye inflammation cases linked to Apellis' Syfovre
WEBJul 17, 2023 · Apellis Pharmaceuticals' Syfovre, after achieving the first FDA approval for advanced eye disease geographic atrophy, has been associated with rare but severe side effects, according to the...
New FDA-approved drug can slow vision loss for those with ... - CBS News
WEBMar 1, 2023 · The Food and Drug Administration recently approved the first drug to treat geographic atrophy, a form of macular degeneration, which affects a person's central vision. Syfovre will be available...